Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ficerafusp alfa plus pembrolizumab weekly versus alternative ficerafusp alfa dosing in first-line recurrent or metastatic head and neck squamous cell carcinoma
2026-526741-10-00Phase 2Authorised
- Sponsor
- Bicara Therapeutics
- Start
- Oct 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 14
01
Overview
Phase 2, randomised, open-label trial of ficerafusp alfa and pembrolizumab in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Bicara Therapeutics. Primary endpoint: Progression-free and alive rate in maintenance phase. Planned start Oct 2026; status: authorised.
02
Drugs
ficerafusp alfapembrolizumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2026-526741-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-526741-10-00.